OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, its Multi-Target T-cell Anti-COVID Vaccine
30 nov. 2021 01h30 HE
|
OSE Immunotherapeutics
New clinical data confirm the good tolerance of CoVepiT and a very good level of T cell response in healthy volunteers vaccinated.Promising preclinical efficacy signals guide development in...
OSE Immunotherapeutics and the FoRT Foundation Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
17 nov. 2021 01h30 HE
|
OSE Immunotherapeutics; FoRT Foundation
Clinical trial sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics.A strategy of combining Opdivo®, a PD-1 targeted...
OSE Immunotherapeutics Presented New Translational Data on Tedopi® and Preclinical Data on PD-1/IL-7 Bifunctional Program BiCKI®-IL-7
16 nov. 2021 01h30 HE
|
OSE Immunotherapeutics
NANTES, France, Nov. 16, 2021 (GLOBE NEWSWIRE) -- November 16, 2021, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented new clinical and translational data on...
OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1, a Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy
15 nov. 2021 01h30 HE
|
OSE Immunotherapeutics
NANTES, France, Nov. 15, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first positive preclinical efficacy data on its novel myeloid cell immune...
OSE Immunotherapeutics to Present New Preclinical Data at Upcoming Bispecific Antibody and Immunology Conferences
19 oct. 2021 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, Oct. 19, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that its Chief Scientific Officer Nicolas Poirier will present the latest...
OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
13 oct. 2021 01h30 HE
|
OSE Immunotherapeutics
NANTES, France, Oct. 13, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that three abstracts have been accepted for presentation at the Society for...
OSE Immunotherapeutics to Host Today a Virtual “Immuno-Oncology R&D Day”
12 oct. 2021 01h30 HE
|
OSE Immunotherapeutics
R&D Day to highlight the Company’s strategy on its leading clinical programs and emerging firs-in-class portfolio in immuno-oncology;Presentations by leading clinicians to feature the latest data...
OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®
11 oct. 2021 01h30 HE
|
OSE Immunotherapeutics
NANTES, France, Oct. 11, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announced today that it has received notice of allowance from the European Patent Office...
Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in combination with anti-PD-1 Antibody Ezabenlimab, in Patients with Advanced Endometrium or Colorectal Tumors
30 sept. 2021 12h30 HE
|
OSE Immunotherapeutics
Dosing of first patient in the expansion phase triggers a milestone payment of €8 million from Boehringer Ingelheim to OSE Immunotherapeutics.Data from the dose escalation Step 1 of the Phase 1 trial...
OSE Immunotherapeutics to Host an “Immuno-Oncology R&D Day” On October 12th, 2021
27 sept. 2021 12h00 HE
|
OSE Immunotherapeutics
NANTES, France, Sept. 27, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that it will host a virtual and in-person R&D Day on Tuesday, October...